Alligator Bioscience
Lund
About Alligator Bioscience
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $27.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: sto:ATORX
- Website: alligatorbioscience.seen
- Phone: 46 4 62 86 42 80
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alligator-bioscience-10898 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.